List of Figures
Figure 1: Emerging Pharmaceutical Market: Brazil, Revenue Forecast, $bn, 2004–2018
Figure 2: Emerging Pharmaceutical Market: Brazil, Market Share by Therapy Area, (%), 2010
Figure 3: Emerging Pharmaceutical Market: Brazil, R&D Restructuring Activities, 2011
Figure 4: Emerging Pharmaceutical Market – Brazil, Key Domestic Players, EMS Sigma Pharma , SWOT Profile, 2011
Figure 5: Emerging Pharmaceutical Market – Brazil, Key Domestic Players, Ache Laboratorios Farmaceuticos, SWOT Profile, 2011
Figure 6: Emerging Pharmaceutical Market – Brazil, Key Domestic Players, Eurofarma, SWOT Profile, 2011
Figure 7: Emerging Pharmaceutical Market – Brazil, Key Domestic Players, Medley Pharmaceuticals, SWOT Profile, 2011
Figure 8: Emerging Pharmaceutical Market – Brazil, Key Domestic Players, Hypermarcas, SWOT Profile, 2011
Figure 9: Emerging Pharmaceutical Market – Brazil, Key Foreign Players, Sanofi, SWOT Profile, 2011
Figure 10: Emerging Pharmaceutical Market – Brazil, Key Foreign Players, Novartis, SWOT Profile, 2011
Figure 11: Emerging Pharmaceutical Market – Brazil, Key Foreign Players, Pfizer, SWOT Profile, 2011
Figure 12: Emerging Pharmaceutical Market – Brazil, Key Foreign Players, Roche, SWOT Profile, 2011
Figure 13: Emerging Pharmaceutical Market: Brazil, Drivers and Barriers in the Brazilian Pharmaceutical Market
Figure 14: Emerging Pharmaceutical Market: Brazil, Healthcare Delivery Opportunities, 2011
Figure 15: Emerging Pharmaceutical Market: Brazil, Healthcare Delivery Barriers, 2011
Figure 16: Emerging Pharmaceutical Market: Brazil, PESTLE Analysis
Figure 17: Emerging Pharmaceutical Market: Brazil, Population Age Structure, (%), 1950–2050
Figure 18: Emerging Pharmaceutical Market: Brazil, Health Indicators, 2011
Figure 19: Emerging Pharmaceutical Market in Brazil, Population Forecast of Brazil, (Million), 2005–2050
Figure 20: Emerging Pharmaceutical Market: Brazil, Number of Deaths by Major Diseases, (%), 2008
Figure 21: Emerging Pharmaceutical Market: Brazil, Population Forecast for HIV/AIDS Prevalence (‘000), 2011-2018
Figure 22: Emerging Pharmaceutical Market: Brazil, Population Forecast for CVD Prevalence (Million), 2011–2018
Figure 23: Emerging Pharmaceutical Market: Brazil, Population Forecast for Diabetes Prevalence (Million), 2011-2018
Figure 24: Emerging Pharmaceutical Market: Brazil, Population Forecast for Cancer Prevalence (‘000), 2011–2018
Figure 25: Emerging Pharmaceutical Market: Brazil, GDP Composition by Sector (%), 2011
Figure 26: Emerging Pharmaceutical Market: Brazil, GDP and Inflation Rates, 2005–2011
Figure 27: Emerging Pharmaceutical Market: Brazil, National Healthcare Expenditure, (% of GDP), 2010
Figure 28: Emerging Pharmaceutical Market: Brazil, Comparative Analysis of Healthcare Expenditure Ratios, Argentina, Mexico and BRIC Countries, (%), 2010
Figure 29: Emerging Pharmaceutical Market: Brazil, Public and Private Distribution, (%), 2008
Figure 30: Emerging Pharmaceutical Market: Brazil, Healthcare Infrastructure, 2008
Figure 31: Emerging Pharmaceutical Market: Brazil, Healthcare Professionals, (%), 2008
Figure 32: Emerging Pharmaceutical Market: Brazil, Hospitals, by Bed Distribution, (%), 2008
Figure 33: Emerging Pharmaceutical Market: Brazil, Regulatory Approval Process for Clinical Trials
Figure 34: Emerging Pharmaceutical Market: Brazil, Drug Registration Process by ANVISA
Figure 35: Emerging Pharmaceutical Market – Brazil, Clinical Trial Market, ($m), 2011–2018
Figure 36: Emerging Pharmaceutical Market – Brazil, Reimbursement, 2011
Figure 37: Emerging Pharmaceutical Market – Brazil, Healthcare Coverage Providers, Plan Members, (%), 2010
Figure 38: Emerging Pharmaceutical Market – Brazil, Healthcare Coverage Providers, Revenue, (%), 2011
Figure 39: Emerging Pharmaceutical Market – Brazil, M&A Deals by Year, 2004–2011
Figure 40: Emerging Pharmaceutical Market – Brazil, M&A Deals by Value, (%), 2004–2011
Figure 41: Emerging Pharmaceutical Market – Brazil, Co-development Deals by Year, 2004–2011
Figure 42: Emerging Pharmaceutical Market – Brazil, Co-development Deals by Value, (%), 2004–2011
Figure 43: Emerging Pharmaceutical Market – Brazil, Licensing Agreements by Year, 2004–2011
Figure 44: Emerging Pharmaceutical Market – Brazil, Licensing Agreements by Value, (%), 2004–2011
Figure 45: Emerging Pharmaceutical Market – Brazil, PPD, Company Profile, 2011
Figure 46: Emerging Pharmaceutical Market – Brazil, PRA International, Company Profile, 2011
Figure 47: Emerging Pharmaceutical Market – Brazil, ICON, Company Profile, 2011
Figure 48: Emerging Pharmaceutical Market – Brazil, Theorem Clinical Research, Company Profile, 2011
Figure 49: Emerging Pharmaceutical Market – Brazil, PAREXEL, Company Profile, 2011
Figure 50: Emerging Pharmaceutical Market – Brazil, Intrials, Company Profile, 2011
Figure 51: Emerging Pharmaceutical Market – Brazil, Eurotrials, Company Profile, 2011
Figure 52: Emerging Pharmaceutical Market – Brazil, PGS Medical/Statistics, Company Profile, 2011
Figure 53: Emerging Pharmaceutical Market – Brazil, INC Research, Company Profile, 2011
Figure 54: Emerging Pharmaceutical Market – Brazil, Chiltern, Company Profile, 2011
Figure 55: Emerging Pharmaceutical Market – Brazil, Covance, Company Profile, 2011
Figure 56: Emerging Pharmaceutical Market – Brazil, Quintiles, Company Profile, 2011